Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry.

Bigdeli TB, Genovese G, Georgakopoulos P, Meyers JL, Peterson RE, Iyegbe CO, Medeiros H, Valderrama J, Achtyes ED, Kotov R, Stahl EA, Abbott C, Azevedo MH, Belliveau RA, Bevilacqua E, Bromet EJ, Byerley W, Carvalho CB, Chapman SB, DeLisi LE, Dumont AL, O'Dushlaine C, Evgrafov OV, Fochtmann LJ, Gage D, Kennedy JL, Kinkead B, Macedo A, Moran JL, Morley CP, Dewan MJ, Nemesh J, Perkins DO, Purcell SM, Rakofsky JJ, Scolnick EM, Sklar BM, Sklar P, Smoller JW, Sullivan PF, Macciardi F, Marder SR, Gur RC, Gur RE, Braff DL; Consortium on the Genetics of Schizophrenia (COGS) Investigators, Nicolini H, Escamilla MA, Vawter MP, Sobell JL, Malaspina D, Lehrer DS, Buckley PF, Rapaport MH, Knowles JA; Genomic Psychiatry Cohort (GPC) Consortium, Fanous AH, Pato MT, McCarroll SA, Pato CN.

Mol Psychiatry. 2019 Oct 7. doi: 10.1038/s41380-019-0517-y. [Epub ahead of print]

PMID:
31591465
2.

The prevalence and impact of psychiatric symptoms in an undiagnosed diseases clinical program.

Waserstein G, Partin C, Cohen D, Schettler P, Kinkead B, Rapaport MH.

PLoS One. 2019 Jun 6;14(6):e0216937. doi: 10.1371/journal.pone.0216937. eCollection 2019.

3.

Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Dunlop BW, LoParo D, Kinkead B, Mletzko-Crowe T, Cole SP, Nemeroff CB, Mayberg HS, Craighead WE.

Am J Psychiatry. 2019 Apr 1;176(4):275-286. doi: 10.1176/appi.ajp.2018.18091075. Epub 2019 Feb 15.

4.

Model structure for protocol adherence utilizing a manualized therapeutic massage intervention.

Larson ER, Kinkead B, Edwards SA, Schettler PJ, Dunlop BW, Rakofsky JJ, Rapaport MH.

J Complement Integr Med. 2018 Oct 12;16(2). pii: /j/jcim.2019.16.issue-2/jcim-2016-0118/jcim-2016-0118.xml. doi: 10.1515/jcim-2016-0118.

PMID:
30312159
5.

Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial.

Kinkead B, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, Edwards SA, Miller AH, Torres MA, Dunlop BW, Rakofsky JJ, Rapaport MH.

Cancer. 2018 Feb 1;124(3):546-554. doi: 10.1002/cncr.31064. Epub 2017 Oct 17.

6.

Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder.

Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, Rothbaum BO, Nemeroff CB, Mayberg HS.

Biol Psychiatry. 2017 Dec 15;82(12):866-874. doi: 10.1016/j.biopsych.2017.06.024. Epub 2017 Jul 4.

7.

Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study.

Dunlop BW, Kelley ME, Aponte-Rivera V, Mletzko-Crowe T, Kinkead B, Ritchie JC, Nemeroff CB, Craighead WE, Mayberg HS; PReDICT Team.

Am J Psychiatry. 2017 Jun 1;174(6):546-556. doi: 10.1176/appi.ajp.2016.16050517. Epub 2017 Mar 24.

8.

Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder.

Dunlop BW, Rajendra JK, Craighead WE, Kelley ME, McGrath CL, Choi KS, Kinkead B, Nemeroff CB, Mayberg HS.

Am J Psychiatry. 2017 Jun 1;174(6):533-545. doi: 10.1176/appi.ajp.2016.16050518. Epub 2017 Mar 24. Erratum in: Am J Psychiatry. 2017 Jun 1;174(6):604.

9.

Acute Swedish Massage Monotherapy Successfully Remediates Symptoms of Generalized Anxiety Disorder: A Proof-of-Concept, Randomized Controlled Study.

Rapaport MH, Schettler P, Larson ER, Edwards SA, Dunlop BW, Rakofsky JJ, Kinkead B.

J Clin Psychiatry. 2016 Jul;77(7):e883-91. doi: 10.4088/JCP.15m10151.

PMID:
27464321
10.

Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.

Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D.

Mol Psychiatry. 2016 Jan;21(1):71-9. doi: 10.1038/mp.2015.22. Epub 2015 Mar 24.

11.

Striatal dopamine receptor plasticity in neurotensin deficient mice.

Chastain LG, Qu H, Bourke CH, Iuvone PM, Dobner PR, Nemeroff CB, Kinkead B.

Behav Brain Res. 2015 Mar 1;280:160-71. doi: 10.1016/j.bbr.2014.11.014. Epub 2014 Nov 15.

12.

A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression.

Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, Hyman Rapaport M.

J Clin Psychiatry. 2015 Jan;76(1):54-61. doi: 10.4088/JCP.14m08986.

PMID:
25272149
13.

Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial.

Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS.

Trials. 2014 Jun 21;15:240. doi: 10.1186/1745-6215-15-240.

14.

The prevalence and severity of depressive symptoms along the spectrum of unipolar depressive disorders: a post hoc analysis.

Rakofsky JJ, Schettler PJ, Kinkead BL, Frank E, Judd LL, Kupfer DJ, Rush AJ, Thase ME, Yonkers KA, Rapaport MH.

J Clin Psychiatry. 2013 Nov;74(11):1084-91. doi: 10.4088/JCP.12m08194.

PMID:
24330894
15.

In vivo dialysis setup with a loop injection valve facilitates retrodialysis studies.

Thrivikraman KV, Kinkead B, Murray KE, Owens MJ.

J Pharmacol Toxicol Methods. 2013 Sep-Oct;68(2):217-224. doi: 10.1016/j.vascn.2013.06.002. Epub 2013 Jul 4.

PMID:
23831608
16.

Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder.

Garlow SJ, Kinkead B, Thase ME, Judd LL, Rush AJ, Yonkers KA, Kupfer DJ, Frank E, Schettler PJ, Rapaport MH.

J Psychiatr Res. 2013 Sep;47(9):1199-203. doi: 10.1016/j.jpsychires.2013.05.025. Epub 2013 Jun 17.

17.

Comprehensive structural, surface-chemical and electrochemical characterization of nickel-based metallic foams.

van Drunen J, Kinkead B, Wang MC, Sourty E, Gates BD, Jerkiewicz G.

ACS Appl Mater Interfaces. 2013 Jul 24;5(14):6712-22. doi: 10.1021/am401606n. Epub 2013 Jun 24.

PMID:
23755737
18.

Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease.

Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammerschmidt T, Heneka MT, Weinshenker D, Levey AI.

Alzheimers Res Ther. 2013 Apr 29;5(2):21. doi: 10.1186/alzrt175. eCollection 2013. Review.

19.

Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial.

Dunlop BW, Binder EB, Cubells JF, Goodman MM, Kelley ME, Kinkead B, Kutner M, Nemeroff CB, Newport DJ, Owens MJ, Pace TW, Ritchie JC, Rivera VA, Westen D, Craighead WE, Mayberg HS.

Trials. 2012 Jul 9;13:106. doi: 10.1186/1745-6215-13-106.

20.

Cerebrospinal fluid substance P-like immunoreactivity correlates with aggression in personality disordered subjects.

Coccaro EF, Lee R, Owens MJ, Kinkead B, Nemeroff CB.

Biol Psychiatry. 2012 Aug 1;72(3):238-43. doi: 10.1016/j.biopsych.2012.02.023. Epub 2012 Mar 24.

PMID:
22449753
21.

The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion.

Cáceda R, Binder EB, Kinkead B, Nemeroff CB.

Schizophr Res. 2012 Apr;136(1-3):88-95. doi: 10.1016/j.schres.2011.10.013. Epub 2011 Nov 21.

22.

Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine.

Bonne O, Gill JM, Luckenbaugh DA, Collins C, Owens MJ, Alesci S, Neumeister A, Yuan P, Kinkead B, Manji HK, Charney DS, Vythilingam M.

J Clin Psychiatry. 2011 Aug;72(8):1124-8. doi: 10.4088/JCP.09m05106blu. Epub 2010 Dec 28.

PMID:
21208596
23.

A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.

Mathew SJ, Vythilingam M, Murrough JW, Zarate CA Jr, Feder A, Luckenbaugh DA, Kinkead B, Parides MK, Trist DG, Bani MS, Bettica PU, Ratti EM, Charney DS.

Eur Neuropsychopharmacol. 2011 Mar;21(3):221-9. doi: 10.1016/j.euroneuro.2010.11.012. Epub 2010 Dec 30.

24.

Electroconvection in nematic liquid crystals via nanoparticle doping.

Urbanski M, Kinkead B, Qi H, Hegmann T, Kitzerow HS.

Nanoscale. 2010 Jul;2(7):1118-21. doi: 10.1039/c0nr00139b. Epub 2010 May 4.

PMID:
20648336
25.

Miscibility and alignment effects of mixed monolayer cyanobiphenyl liquid-crystal-capped gold nanoparticles in nematic cyanobiphenyl liquid crystal hosts.

Qi H, Kinkead B, Marx VM, Zhang HR, Hegmann T.

Chemphyschem. 2009 Jun 2;10(8):1211-8. doi: 10.1002/cphc.200800765.

PMID:
19334026
26.

Polymorphisms in the serotonin reuptake transporter gene modify the consequences of social status on metabolic health in female rhesus monkeys.

Jarrell H, Hoffman JB, Kaplan JR, Berga S, Kinkead B, Wilson ME.

Physiol Behav. 2008 Mar 18;93(4-5):807-19. doi: 10.1016/j.physbeh.2007.11.042. Epub 2007 Dec 4.

27.
28.

Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats.

Kinkead B, Yan F, Owens MJ, Nemeroff CB.

Psychoneuroendocrinology. 2008 Feb;33(2):178-87. Epub 2007 Dec 21.

29.

Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.

Carpenter LL, Bayat L, Moreno F, Kling MA, Price LH, Tyrka AR, Kinkead B, Owens MJ, Nemeroff CB.

Psychiatry Res. 2008 Jan 15;157(1-3):123-9. Epub 2007 Oct 31.

PMID:
17976740
30.
31.

Involvement of neuropeptide systems in schizophrenia: human studies.

Cáceda R, Kinkead B, Nemeroff CB.

Int Rev Neurobiol. 2007;78:327-76. Review.

PMID:
17349866
32.

Neurotensin: role in psychiatric and neurological diseases.

Cáceda R, Kinkead B, Nemeroff CB.

Peptides. 2006 Oct;27(10):2385-404. Epub 2006 Aug 4. Review.

PMID:
16891042
33.

Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits.

Shilling PD, Kinkead B, Murray T, Melendez G, Nemeroff CB, Feifel D.

Biol Psychiatry. 2006 Dec 1;60(11):1278-81. Epub 2006 Jun 30.

PMID:
16814260
34.

Novel treatments of schizophrenia: targeting the neurotensin system.

Kinkead B, Nemeroff CB.

CNS Neurol Disord Drug Targets. 2006 Apr;5(2):205-18. Review.

PMID:
16611093
35.

Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression.

Geracioti TD Jr, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB.

Am J Psychiatry. 2006 Apr;163(4):637-43.

PMID:
16585438
36.

Ketamine-xylazine-acepromazine anesthesia and postoperative recovery in rats.

Welberg LA, Kinkead B, Thrivikraman K, Huerkamp MJ, Nemeroff CB, Plotsky PM.

J Am Assoc Lab Anim Sci. 2006 Mar;45(2):13-20.

PMID:
16542037
37.

Algorithmically designed peptides ameliorate behavioral defects in animal model of ADHD by an allosteric mechanism.

Kinkead B, Selz KA, Owens MJ, Mandell AJ.

J Neurosci Methods. 2006 Feb 15;151(1):68-81. Epub 2006 Jan 19.

PMID:
16423408
38.
39.

Genetic analysis of the hypothalamic neurotensin system.

Garlow SJ, Boone E, Kinkead B, Nemeroff CB.

Neuropsychopharmacology. 2006 Mar;31(3):535-43.

40.

The electrophysiological effects of neurotensin on spontaneously active neurons in the nucleus accumbens: an in vivo study.

Stowe ZN, Landry JC, Tang Z, Owens MJ, Kinkead B, Nemeroff CB.

Synapse. 2005 Dec 1;58(3):165-72.

PMID:
16108007
41.

Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine.

Kinkead B, Dobner PR, Egnatashvili V, Murray T, Deitemeyer N, Nemeroff CB.

J Pharmacol Exp Ther. 2005 Oct;315(1):256-64. Epub 2005 Jun 29.

PMID:
15987829
42.
43.

Neurotensin, schizophrenia, and antipsychotic drug action.

Kinkead B, Nemeroff CB.

Int Rev Neurobiol. 2004;59:327-49. Review.

PMID:
15006494
44.

Cellular and behavioral effects of D2 dopamine receptor hydrophobic eigenmode-targeted peptide ligands.

Mandell AJ, Selz KA, Owens MJ, Kinkead B, Shlesinger MF, Gutman DA, Arguragi V.

Neuropsychopharmacology. 2003 Jul;28 Suppl 1:S98-107.

45.

Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?

Cáceda R, Kinkead B, Nemeroff CB.

Semin Clin Neuropsychiatry. 2003 Apr;8(2):94-108. Review.

PMID:
12728409
46.

Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing.

Nemeroff CB, Kinkead B, Goldstein J.

J Clin Psychiatry. 2002;63 Suppl 13:5-11. Review.

47.

Neurotensin: an endogenous antipsychotic?

Kinkead B, Nemeroff CB.

Curr Opin Pharmacol. 2002 Feb;2(1):99-103. Review.

PMID:
11786316
48.

The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs.

Binder EB, Kinkead B, Owens MJ, Nemeroff CB.

Biol Psychiatry. 2001 Dec 1;50(11):856-72. Review.

PMID:
11743941
49.

Neurotensin and dopamine interactions.

Binder EB, Kinkead B, Owens MJ, Nemeroff CB.

Pharmacol Rev. 2001 Dec;53(4):453-86. Review.

PMID:
11734615

Supplemental Content

Loading ...
Support Center